Beppu Naohito, Matsubara Nagahide, Noda Masashi, Yamano Tomoki, Kakuno Ayako, Doi Hiroshi, Kamikonya Norihiko, Kimura Fumihiko, Yamanaka Naoki, Yanagi Hidenori, Tomita Naohiro
Department of Surgery, Hyogo College of Medicine, Hyogo, Japan.
Department of Surgery, Hyogo College of Medicine, Hyogo, Japan.
Surgery. 2015 Jul;158(1):225-35. doi: 10.1016/j.surg.2015.03.014. Epub 2015 Apr 18.
The aim of this study was to compare the short- and long-term outcomes between short-course radiotherapy with delayed surgery (SRT-delay) and a standard conventional chemoradiotherapy (CRT) regimen.
Two collaborating institutions adopted different regimens; the SRT-delay regimen was selected by Meiwa Hospital and the CRT regimen was selected by Hyogo College of Medicine. The inclusion criteria were T3 middle and low rectal cancer patients treated with radical surgery after preoperative therapy. The median follow-up period was 44 months (range, 12-85).
From 2007 to 2013, 104 patients were treated using the SRT-delay regimen and 61 patients were treated using the CRT regimen. The pretreatment characteristics of the 2 groups were not significantly different. The sphincter-preserving rate (93.3%, 85.2%), T downstaging (37.5%, 37.7%), ypN(-) (74.0%, 67.2%), postoperative complications and the bowel, and urinary and sexual functioning of the SRT-delay regimen were noninferior to those of the CRT regimen. The 3-year local recurrence-free survival, recurrence-free survival, and overall survival in the SRT-delay and CRT groups were 90.6% and 90.6% (P = .764), 83.8% and 78.3% (P = .687) and 96.0% and 92.8% (P = .833), respectively.
The SRT-delay regimen was noninferior in terms of the downstaging effect, and oncologic and functional outcomes compared with the CRT regimen for T3 middle and low rectal cancer.
本研究旨在比较短程放疗联合延迟手术(SRT-delay)与标准传统放化疗(CRT)方案的短期和长期疗效。
两家合作机构采用不同方案;SRT-delay方案由美和医院选择,CRT方案由兵库医科大学选择。纳入标准为术前治疗后接受根治性手术的T3期低位和中位直肠癌患者。中位随访期为44个月(范围12 - 85个月)。
2007年至2013年,104例患者采用SRT-delay方案治疗,61例患者采用CRT方案治疗。两组的预处理特征无显著差异。SRT-delay方案的保肛率(93.3%,85.2%)、T分期降低(37.5%,37.7%)、ypN(-)(74.0%,67.2%)、术后并发症以及肠道、泌尿和性功能不劣于CRT方案。SRT-delay组和CRT组的3年局部无复发生存率、无复发生存率和总生存率分别为90.6%和90.6%(P = 0.764)、83.8%和78.3%(P = 0.687)以及96.0%和92.8%(P = 0.833)。
对于T3期低位和中位直肠癌,SRT-delay方案在分期降低效果、肿瘤学和功能结局方面不劣于CRT方案。